We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

134 hedge funds and large institutions have $61.3M invested in SANGAMO THERAPEUTICS INC in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more call options, than puts

Call options by funds: $91K | Put options by funds: $81K

3.95% less ownership

Funds ownership: 61.65%57.7% (-4%)

12% less funds holding

Funds holding: 152134 (-18)

33% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 49

55% less capital invested

Capital invested by funds: $137M → $61.3M (-$76.1M)

65% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 26

Holders
134
Holders Change
-18
Holders Change %
-11.84%
% of All Funds
2.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
33
Reduced
49
Closed
26
Calls
$91K
Puts
$81K
Net Calls
+$10K
Net Calls Change
+$87K
Name Holding Trade Value Shares
Change
Change in
Stake
WA
1
Wasatch Advisors
Utah
$10.8M +$1M +934,341 +5%
BlackRock
2
BlackRock
New York
$9.48M -$98.5K -92,020 -0.6%
Vanguard Group
3
Vanguard Group
Pennsylvania
$7.52M +$141K +131,833 +1%
RCMU
4
Rokos Capital Management (UK)
United Kingdom
$3.94M
Citadel Advisors
5
Citadel Advisors
Florida
$2.72M +$40.6K +37,902 +0.8%
CS
6
Credit Suisse
Switzerland
$2.22M
Geode Capital Management
7
Geode Capital Management
Massachusetts
$1.8M +$152K +142,174 +5%
Acadian Asset Management
8
Acadian Asset Management
Massachusetts
$1.75M +$113K +105,789 +4%
State Street
9
State Street
Massachusetts
$1.61M +$32.6K +30,458 +1%
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$1.5M +$133K +124,609 +5%
Renaissance Technologies
11
Renaissance Technologies
New York
$1.42M -$751K -701,742 -23%
ECM
12
ExodusPoint Capital Management
New York
$1.13M -$207K -193,208 -9%
Goldman Sachs
13
Goldman Sachs
New York
$975K +$540K +504,701 +45%
JP Morgan Chase
14
JP Morgan Chase
New York
$843K -$81.7K -76,270 -5%
LFCM
15
Long Focus Capital Management
Puerto Rico
$823K +$107K +100,000 +8%
Hudson Bay Capital Management
16
Hudson Bay Capital Management
Connecticut
$779K -$28.4K -26,500 -2%
Bank of America
17
Bank of America
North Carolina
$740K +$901K +841,460 +214%
Charles Schwab
18
Charles Schwab
California
$714K +$276K +257,676 +28%
Northern Trust
19
Northern Trust
Illinois
$714K -$12.9K -12,022 -1%
HighTower Advisors
20
HighTower Advisors
Illinois
$608K -$14.7K -13,725 -1%
Assenagon Asset Management
21
Assenagon Asset Management
Luxembourg
$542K -$39 -36 -0%
Two Sigma Investments
22
Two Sigma Investments
New York
$538K -$365K -340,792 -28%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$506K -$180K -167,900 -17%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$482K -$790K -737,729 -48%
Morgan Stanley
25
Morgan Stanley
New York
$458K -$14.9K -13,916 -2%

SGMO Hedge Fund Activity: Q3 2023 in Review

134 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2023, worth a combined $61.3M — down 55% from $137M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of SGMO and 9 opened new positions — a net loss of 17 holders — while 49 trimmed existing stakes and 33 added.

The largest buyer was Wasatch Advisors, adding an estimated $1M. The largest seller was Globeflex Capital, exiting entirely with an estimated $907K sold.

  • 134 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2023, down from 152 in Q2 2023.
  • Funds reported $61.3M of SANGAMO THERAPEUTICS INC stock for Q3 2023, down 55% quarter-over-quarter.
  • 9 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2023 and 26 closed out, a net change of -17 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q3 2023 was Wasatch Advisors, an estimated $1M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q3 2023 was Globeflex Capital, an estimated $907K sold.

Based on aggregated 13F filings for Q3 2023.